Descovy is a medicine for HIV. It is used with other HIV medicines to treat HIV, and on its own to help prevent HIV (called PrEP) in people at risk. It is a pill taken once a day, and it works by stopping the virus from making copies of itself.
Every report comes from a Lived member, sent anonymously.
Have you tried Descovy (Emtricitabine / Tenofovir Alafenamide) for HIV Infection?
Descovy is a prescription tablet that combines two HIV medicines, emtricitabine and tenofovir alafenamide. It has two quite different uses. The first is treating HIV. Here Descovy is never used alone: it is taken together with other HIV medicines to make a complete regimen. It is approved for this in adults and in children who weigh at least 14 kg (about 31 pounds), with some limits on which partner medicines children can use. The same two ingredients also come built into some single-tablet regimens, such as Biktarvy, which adds a third drug. The second is preventing HIV, known as PrEP (pre-exposure prophylaxis). People who do not have HIV take Descovy daily to lower their chance of getting it through sex. This use is approved for adults and adolescents who weigh at least 35 kg (about 77 pounds), but not for people whose risk comes from receptive vaginal sex, because it has not been tested well enough in that group. Other approved PrEP options include the older daily pill Truvada (emtricitabine with a different form of tenofovir) and long-acting injections, Apretude and Yeztugo; a prescriber can say which fits.
HIV is a virus that inserts its genes into the body's immune cells. To do that, it first has to copy its genetic material into DNA, using an enzyme called reverse transcriptase. Both medicines in Descovy belong to a class called nucleoside reverse transcriptase inhibitors (NRTIs). Inside the cell, each is converted into a look-alike of one of the building blocks of DNA. When the virus's enzyme picks up one of these look-alikes, the new DNA strand cannot be extended, and the copy is left unfinished. In someone with HIV, this slows the virus's ability to multiply, and the other medicines in the regimen add to that effect. In someone taking PrEP, enough medicine in the body can stop the virus from establishing an infection after an exposure. Tenofovir alafenamide is a newer form of tenofovir that is converted to its active form mainly inside cells, which lets it work at a much smaller dose than the older form in Truvada.
Descovy is one tablet taken by mouth once a day, with or without food. Most adults and larger adolescents take the 200 mg/25 mg tablet. Children who weigh 14 to under 25 kg take a smaller tablet, and the prescriber chooses the partner HIV medicines and their doses. People on hemodialysis take their dose after dialysis on dialysis days. Taking it every day matters for both uses. For PrEP, protection is closely tied to having enough medicine in the body, and missed doses raise the chance of getting HIV. The approved way to take Descovy for PrEP is daily; taking pills only around the time of sex ("on-demand" or "2-1-1" PrEP) is not FDA-approved or CDC-recommended. For treatment, even a short break can let the amount of virus rise and the virus become resistant, meaning harder to treat. Refill before running out, and ask the pharmacist what to do if a dose is missed. Before starting, you will have a test for hepatitis B and blood and urine tests of kidney function. Anyone starting PrEP needs a negative HIV test right before the first dose.
Many people notice few side effects. In treatment studies, nausea was the most common; in the main PrEP study, diarrhea was. These are usually mild. Compared with Truvada in that PrEP study, people on Descovy had slightly better bone density results and a small rise in triglycerides (a type of blood fat), though the long-term meaning of those differences is not known. Kidney problems, including a rare form of kidney damage called Fanconi syndrome, have been reported with medicines containing tenofovir alafenamide. They are uncommon and usually picked up by the routine blood and urine tests rather than by symptoms. Two rare reactions are serious enough to recognize. Lactic acidosis is a buildup of acid in the blood that can be life-threatening. Contact the prescriber right away for unusual weakness or tiredness, unusual muscle pain, fast breathing or shortness of breath, stomach pain with nausea and vomiting, cold or blue hands and feet, dizziness, or a fast or irregular heartbeat. Severe liver problems are also rare; contact the prescriber right away for yellow skin or eyes, dark tea-colored urine, pale stools, or several days of poor appetite with nausea or stomach pain. In people with HIV who start treatment, a recovering immune system can sometimes react to infections that were hiding in the body. Report any new signs of infection after starting HIV medicines promptly.
Descovy carries two FDA boxed warnings, the agency's most prominent kind. The first concerns hepatitis B, a viral liver infection. In people who have hepatitis B, stopping Descovy can cause a severe flare of liver inflammation, which can lead to liver failure. That is why everyone is tested for hepatitis B before starting. If you have hepatitis B, do not stop Descovy or let your supply run out without a plan from your prescriber, who will check your liver for several months afterward and may start a hepatitis B medicine. People without hepatitis B should be offered the vaccine. The second concerns PrEP. Descovy alone is not enough to treat HIV, so if someone has an HIV infection that has not been detected and takes only Descovy, the virus can become resistant to these medicines. Descovy for PrEP is therefore started only after a negative HIV test and continued with HIV testing at least every three months, and after any new sexually transmitted infection. Some HIV tests miss very recent infection, so tell the prescriber right away about a possible exposure or a flu-like illness (fever, tiredness, sore throat, rash, aches, night sweats or swollen glands) in the month before starting or at any time while taking it. A few medicines lower the level of tenofovir alafenamide enough to weaken it. The tuberculosis antibiotics rifampin, rifabutin and rifapentine, and the herbal supplement St. John's wort, are not recommended with Descovy. Some seizure medicines, including carbamazepine, oxcarbazepine, phenobarbital and phenytoin, call for an alternative. Medicines that strain the kidneys, such as regular or high-dose use of nonsteroidal anti-inflammatory pain relievers (NSAIDs) like ibuprofen, can add to kidney risk. Descovy is not recommended for people with severely reduced kidney function unless they are on regular hemodialysis. If you are pregnant, planning pregnancy or breastfeeding, talk with the prescriber. For people with HIV, breastfeeding carries a risk of passing HIV to the baby.
For HIV treatment, Descovy and its partner medicine aim to bring the amount of virus in the blood down until standard tests can no longer measure it, known as an undetectable viral load. Regular blood tests track this along with kidney function. Treatment is long-term, and staying on it consistently is what keeps the virus controlled. For PrEP, CDC estimates that PrEP taken as prescribed lowers the risk of getting HIV from sex by about 99%. How long Descovy takes to reach full protection after starting is not known, so ask the prescriber when to rely on it. PrEP means a visit about every three months for an HIV test, other sexually transmitted infection testing and a refill, plus periodic kidney tests. Descovy does not prevent other sexually transmitted infections such as syphilis, gonorrhea or chlamydia, so condoms and regular testing remain part of prevention. If daily pills stop fitting your life, or you want to stop PrEP, talk with the prescriber first; options include another pill or long-acting injections.
Last reviewed • Oct 2026
Educational content, not medical advice.
I am currently taking Descovy for prep and have experienced no side effects from it. However, sometimes I am not very good at taking a daily pill amd am curious if anyone has any experience with the new twice-yearly shot for prevention...